This Biotech Company Says That It's Looking To Deliver A Breakthrough In Psychiatric Medicine

This Biotech Company Says That It's Looking To Deliver A Breakthrough In Psychiatric Medicine ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ Pasithea Therapeutics Corp. [KTTA+3.69%+ Free Alerts]( is a biotech company with a goal of investigating novel drug treatments to provide more effective relief to the estimated [792 million]( people around the world living with a mental health disorder. Launched in 2020, the company emerged just as the COVID pandemic began sweeping the globe, triggering a [25%]( spike in depression and anxiety cases. While the pandemic caused rates of mental health disorders to rise faster than usual, the need for new breakthrough treatments has arguably existed for decades. Approximately [30%]( of people diagnosed with depression don’t respond to the current standard medications, and it’s been some time since novel compounds have hit the market. For the past 20 or so years, much of the industry has been focused on [refining the existing antidepressants]( and mood stabilizers to decrease their side effects. Pasithea reports that it wants to change that by integrating immunology and neuroscience to explore new drugs and gain a better understanding of the psychiatric and neurological diseases millions of people are suffering from. Safer, More Effective Drugs For Patients With Inadequate Options? Pasithea’s current pipeline includes PAT 101 for schizophrenia and bipolar disorder and PAT 102 for multiple sclerosis, both in the preclinical discovery phase. Like depression, schizophrenia has a high rate of treatment resistance with between [10% and 30%]( of patients not responding to the antipsychotics available. Even for patients who do respond to treatment, the improvement can be minor and not enough to offset the side effects. Reportedly, the best treatment currently available for treatment-resistant schizophrenia is clozapine, which is only 30% effective at controlling schizophrenic episodes. In addition to a low efficacy rate, clozapine also comes with safety issues, including low blood pressure and seizures. Similarly, the best available treatment for bipolar disorder — a combination of antidepressants and antipsychotics or mood stabilizers — helps prevent manic episodes and hospitalization, but the combined treatment carries [many side effects]( that can make them tough to stick with for the long term. For multiple sclerosis, the most effective drugs for preventing disease progression and relapses work well but carry high risks including [severe disability and even death](. In short, while treatments exist for all of these, shortcomings and safety issues mean that patients sometimes have to make difficult choices and tradeoffs to get relief. That’s why companies like Pasithea are looking for new compounds that could provide better relief with fewer safety risks and side effects. In October, for example, the company [partnered]( with Evotec SE [EVO-0.46%+ Free Alerts]( to begin developing a new small-molecule therapeutic that targets the neuro-inflammatory pathways associated with schizophrenia and depression. In February, it partnered with Hooke Laboratories to work on a safe, tolerizing vaccine for Multiple Sclerosis. Just last week the company announced the acquisition of Alpha-5 Integrin, which has a lead therapeutic candidate with a novel mechanism of action in the treatment of ALS. Clinical Partnerships May Provide Relief For Patients And Immediate Revenue Stream For Pasithea In the U.K., for example, the biotech is working with Zen Healthcare, which owns three holistic medical and wellness clinics across the country, to make Pasithea’s ketamine infusion treatments available to patients in the UK. The company is also offering SPRAVATO, a ketamine-derivative administered via nasal spray manufactured by Johnson & Johnson [JNJ+0.32%+ Free Alerts]( subsidiary Janssen Pharmaceuticals. In the United States, Pasithea has partnered with The I.V. Doc — a mobile clinic service that provides intravenous treatments to patients in their homes — to roll out [in-home ketamine treatments]( for patients across New York and California, with more states being added. It also [announced]( the launch of an in-person clinic in Los Angeles that will offer ketamine infusions along with a range of other cutting-edge treatments, including repetitive transcranial magnetic stimulation (rTMS), a brain-stimulation technique shown to help with certain drug-resistant mental health disorders. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. This website is wholly owned by tradigital marketing group, inc. (d/b/a “tradigital ir”). Our reports are advertorials and are for general information purposes only. never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our email list, as well as any social networking platforms we may use. please note well: tradigital ir and its employees are not registered investment advisors, broker-dealers, or member(s) of any association for other research providers in any jurisdiction whatsoever. release of liability: through use of this website, viewing or using you agree to hold tradigital ir, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. tradigital ir encourages readers and investors to supplement the information in these reports with independent research and other professional advice. all information on featured companies is provided by the companies profiled or is available from public sources and tradigital ir makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. none of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. instead, tradigital ir strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. tradigital ir’s full disclosure is to be read and fully understood before using tradigital ir's website, or joining tradigital ir's email or text list. From time to time, tradigital ir will disseminate information about a company via website, email, sms, and other points of media. by viewing tradigital ir's website and/or reading tradigital ir's email or text newsletter you are agreeing ----> . all potential percentage gains discussed in any communications are based on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising companies for monetary compensation. in compliance with section 17(b) of the securities act we are disclosing that we have been compensated a fee pursuant to an agreement between tradigital and pasithea therapeutics corp. tradigital was hired for a period beginning january 2022 and ending march 2022 to publicly disseminate information about pasithea therapeutics corp. via website, email, and sms. We were paid three hundred ninety-four thousand usd via ach. Subsequently, we were paid four hundred ninety-nine thousand usd via ach to publicly disseminate information about pasithea therapeutics corp. via website, email, and sms. We own one hundred fifty thousand restricted common shares of pasithea therapeutics corp., which are eligible for sale on 03/18/2022. For the purpose of this disclaimer, we suggest that you assume we will sell all of our shares once the restriction is lifted on 03/18/2022. Readers are advised to review sec periodic reports: forms 10-q, 10k, form 8-k, insider reports, forms 3, 4, 5 schedule 13d. tradigital ir is compliant with the can-spam act of 2003. tradigital ir does not offer investment advice or analysis, and tradigital ir further urges you to consult your own independent tax, business, financial, and investment advisors. investing in micro-cap, small-cap, and growth securities is highly speculative and carries an extremely high degree of risk. it is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.the private securities litigation reform act of 1995 provides investors a safe harbor in regard to forward-looking statements. any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events, or performance are not statements of historical fact may be forward-looking statements. forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. understand there is no guarantee past performance will be indicative of future results in preparing this publication, tradigital ir has relied upon information supplied by its clients, as well as its clients’ publicly available information and press releases which it believes to be reliable; however, such reliability can not be guaranteed. investors should not rely on the information contained on this website. rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, tradigital ir and its owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. tradigital ir is not responsible for any claims made by the companies advertised herein, nor is tradigital ir responsible for any other promotional firm, its program, or its structure. tradigital ir is not affiliated with any exchange, electronic quotation system, the securities exchange commission, or finra. No longer want to receive these emails? [Unsubscribe](. TradigitalIR 12 E 49th Street, 11th Fl. New York, NY 10017 ‌